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SCIENTIFIC OPINION 
Scientific Opinion on the substantiation of a health claim related to choline 
and “development of brain” pursuant to Article 14 of 
Regulation (EC) No 1924/2006
1
 
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)
2,3
 
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT 
Following an application from Specialised Nutrition Europe (formerly IDACE), submitted for authorisation of a 
health claim pursuant to Article 14 of Regulation (EC) No 1924/2006 via the Competent Authority of France, the 
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on the 
scientific substantiation of a health claim related to choline and “development of brain”. The food constituent, 
choline, which is the subject of the health claim, is sufficiently characterised. The claimed effect proposed by the 
applicant is “development of brain” and the target population is infants and young children from birth to three 
years of age. Taking into account that no evidence was provided for an effect of dietary choline deficiency in the 
normal development of the brain in infants and young children, the Panel considers that the claimed effect, 
“development of brain” for infants and young children from birth to three years in relation to dietary choline, is 
not sufficiently defined for a scientific evaluation. The Panel considers that the claimed effect is general and 
non-specific, and does not refer to any specific health claim as required by Regulation (EC) No 1924/2006. 
© European Food Safety Authority, 2014 
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SUMMARY 
Following an application from Specialised Nutrition Europe (formerly IDACE), submitted for 
authorisation of a health claim pursuant to Article 14 of Regulation (EC) No 1924/2006 via the 
Competent Authority of France, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 
was asked to deliver an opinion on the scientific substantiation of a health claim related to choline and 
“development of brain”. 
The scope of the application was proposed to fall under a health claim referring to children’s 
development and health. 
The food constituent that is the subject of the health claim is choline, which is measurable in foods by 
established methods. The Panel considers that choline is sufficiently characterised. 
The claimed effect proposed by the applicant is “development of brain”. The target population 
proposed by the applicant is infants and young children from birth to three years of age. 
Claims on the maintenance of (unspecified) functions of the nervous system have been evaluated by 
the Panel with a positive outcome for some essential nutrients on the basis of a well-established 
biochemical role of such nutrients in neural transmission, or deficiency symptoms involving the 
nervous system.  
As choline can be synthesised endogenously and it has not been established that dietary choline 
deficiency in humans is associated with impaired brain development or function, claims on the 
improvement, maintenance or reduced loss of (unspecified) neural, brain or psychological functions in 
general are not sufficiently defined for a scientific evaluation. No specific function of the nervous 
system was identified by the applicant as the subject of the claim.  
Taking into account that no evidence was provided for an effect of dietary choline deficiency in the 
normal development of the brain in infants and young children, the Panel considers that the claimed 
effect, “development of brain” for infants and young children from birth to three years in relation to 
dietary choline, is not sufficiently defined for a scientific evaluation.  
The Panel considers that the claimed effect is general and non-specific, and does not refer to any 
specific health claim as required by Regulation (EC) No 1924/2006. 
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BACKGROUND 
Regulation (EC) No 1924/2006
4
 harmonises the provisions that relate to nutrition and health claims, 
and establishes rules governing the Community authorisation of health claims made on foods. As a 
rule, health claims are prohibited unless they comply with the general and specific requirements of 
this Regulation, are authorised in accordance with this Regulation, and are included in the lists of 
authorised claims provided for in Articles 13 and 14 thereof. In particular, Articles 14 to 17 of this 
Regulation lay down provisions for the authorisation and subsequent inclusion of reduction of disease 
risk claims and claims referring to children’s development and health in a Community list of 
permitted claims. 
According to Article 15 of this Regulation, an application for authorisation shall be submitted by the 
applicant to the national competent authority of a Member State, which will make the application and 
any supplementary information supplied by the applicant available to the European Food Safety 
Authority (EFSA). 
STEPS TAKEN BY EFSA 
 The application was received on 14/02/2008. 
 The scope of the application was proposed to fall under a health claim referring to children’s 
development and health. 
 On 26/03/2008, during the validation process of the application, EFSA sent a request to the 
applicant asking it to provide missing information. 
 On 06/08/2013, EFSA received the missing information as submitted by the applicant. 
 The scientific evaluation procedure started on 04/10/2013. 
 On 21/11/2013, the Working Group on Claims of the NDA Panel agreed on a list of questions 
for the applicant to provide additional information to accompany the application and the clock 
was stopped on 29/11/2013.  
 On 21/01/2014, EFSA received the requested information and the clock was restarted, in 
compliance with Article 16(1) of Regulation (EC) No 1924/2006. 
 During its meeting on 10/04/2014, the NDA Panel, having evaluated the data submitted, 
adopted an opinion on the scientific substantiation of a health claim related to choline and 
“development of brain”. 
TERMS OF REFERENCE 
EFSA is requested to evaluate the scientific data submitted by the applicant in accordance with 
Article 16 of Regulation (EC) No 1924/2006. On the basis of that evaluation, EFSA will issue an 
opinion on the scientific substantiation of a health claim related to: choline and “development of 
brain”. 
EFSA DISCLAIMER 
The present opinion does not constitute, and cannot be construed as, an authorisation for the 
marketing of choline a positive assessment of its safety, nor a decision on whether choline is, or is 
not, classified as a foodstuff. It should be noted that such an assessment is not foreseen in the 
framework of Regulation (EC) No 1924/2006. 
                                                     
4 Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and 
health claims made on foods. OJ L 404, 30.12.2006, p. 9–25. 
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It should also be highlighted that the scope, the proposed wording of the claim, and the conditions of 
use as proposed by the applicant may be subject to changes, pending the outcome of the authorisation 
procedure foreseen in Article 17 of Regulation (EC) No 1924/2006. 
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INFORMATION PROVIDED BY THE APPLICANT 
Applicant’s name and address: Specialised Nutrition Europe (formerly IDACE), 9-31 Avenue des 
Nerviens, 1040, Brussels, Belgium. 
Food/constituent as stated by the applicant 
According to the applicant, the food constituent for which the claim is made is choline. 
Health relationship as claimed by the applicant 
According to the applicant, choline is needed for the development of brain of infants and young 
children from birth to three years. 
Wording of the health claim as proposed by the applicant 
The applicant has proposed the following wording for the health claim: “choline is needed for the 
development of brain of infants and young children from birth to three years”. 
As equivalent alternative wordings, the applicant has also proposed: “choline/is needed for/is 
involved in/is important for/plays an important role for/is necessary for/participates to/contributed 
to/the development of/the normal development of/the function of /the normal function/brain”. 
Specific conditions of use as proposed by the applicant 
According to the applicant, the target population is infants (from birth onwards) and young children 
(until three years of age) as defined in Directives 89/398/EEC, 2006/141/EC, and Directive 
2006/125/EC. 
Those foods are exclusively intended for the category of infants and young children, and in line with 
the composition laid down in the specific directives. 
The Institute of Medicine Recommendations for Adequate Intake published in 1998, are the following 
(FNB 1998): 
- Infants 0-5 months: 125 mg/ day  
- Infants 6-11 months: 150 mg/ day 
- Young children 1-3 years: 200 mg/day 
According to the applicant, the quantity needed to achieve the claimed effect is: 
- For infant formulae, the content in choline should be within the range set in 
Directive 2006/141/EC. 
- For follow-on formulae, foods for special medical purposes, processed cereal-based foods and 
baby foods and foods intended for infants and young children, the content in choline should 
reach at least 15 % of the Adequate Intake defined above in 100 g or 100 mL of the product.  
Choline and “development of brain” 
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ASSESSMENT 
1. Characterisation of the food/constituent 
The food constituent that is the subject of the health claim is choline. 
Choline (2-hydroxyethyl-N,N,N-trimethylammonium) is a quaternary ammonium cation generally 
present in foods with a chloride counter-ion (chloride salt). It can also be bound to an acetyl group 
(acetylcholine), to a cytidine diphosphate group (citicoline) or, mainly, to a phosphatidyl group 
(lecithin). Choline is synthesised in the body.  
Choline is measurable in foods by established methods. 
Choline occurs naturally in foods and is authorised for addition to foods (Annex III of Directive 
2006/141/EC
5




). This evaluation applies 
to choline naturally present in foods and those forms authorised for addition to foods (Annex III of 
Directive 2006/141/EC, Annex IV of Directive 2006/125/EC, Directive 2001/15/EC). 
The Panel considers that the food constituent, choline, which is the subject of the health claim, is 
sufficiently characterised. 
2. Relevance of the claimed effect to human health 
The claimed effect proposed by the applicant is “development of brain”. The target population 
proposed by the applicant is infants and young children from birth to three years of age. 
Claims on the maintenance of (unspecified) functions of the nervous system have been evaluated by 
the Panel with a positive outcome for some essential nutrients. The scientific substantiation of these 
claims was based on the well-established biochemical role of such nutrients in neural transmission, or 
on deficiency symptoms involving the nervous system (e.g. EFSA NDA Panel, 2009a, b, c, d), rather 
than on weighing the evidence. The use of unspecified functions to substantiate such claims is 
because symptoms of deficiency of a nutrient can result from effects on multiple physiological 
functions, and it is sometimes not possible or appropriate to single out a precise function that is 
affected by deficiency of that nutrient in a particular organ or system. 
Taking into account that choline can be synthesised endogenously and that it has not been established 
that dietary choline deficiency in humans is associated with impaired brain development or function, 
claims on the improvement, maintenance or reduced loss of (unspecified) neural, brain or 
psychological functions in general are not sufficiently defined for a scientific evaluation. The specific 
function of the nervous system which is the subject of the claim, together with appropriate outcome 
measures which may be used for the scientific evaluation of the claimed effect in vivo in humans, 
must be identified (EFSA NDA Panel, 2012).  
Therefore, EFSA requested the applicant to indicate the specific physiological function of the nervous 
system that is the subject of the health claim, together with the outcome measure(s) which could be 
used for the scientific evaluation of that function. 
                                                     
5 Commission Directive 2006/141/EC of 22 December 2006 on infant formulae and follow-on formulae and amending 
Directive 1999/21/EC Text with EEA relevance. OJ L 401, 30.12.2006, p. 1–33. 
6 Commission Directive 2006/125/EC of 5 December 2006 on processed cereal-based foods and baby foods for infants and 
young children. OJ L 339, 6.12.2006, p. 16–35. 
7 Commission Directive 2001/15/EC of 15 February 2001 on substances that may be added for specific nutritional purposes 
in foods for particular nutritional uses. OJ L 52, 22.2.2001, p. 19–25. 
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In reply, the applicant did not indicate a specific physiological function of the nervous system to be 
the subject of the health claim. 
The Panel notes that the references provided by the applicant as being pertinent to the health claim 
investigated several outcome measures (e.g. brain concentration of choline or choline-containing 
compounds, choline status, DNA damage and apoptosis in peripheral lymphocytes, verbal memory, 
visual function, occurrence of headache, dizziness, motor dysfunction, and memory problems). The 
Panel considers that from the references provided it is not possible to establish the physiological 
function of the nervous system that is the subject of the health claim. 
Taking into account that no evidence was provided for an effect of dietary choline deficiency in the 
normal development of the brain in infants and young children, the Panel considers that the claimed 
effect, “development of brain” for infants and young children from birth to three years in relation to 
dietary choline, is not sufficiently defined for a scientific evaluation.  
The Panel considers that the claimed effect is general and non-specific, and does not refer to any 
specific health claim as required by Regulation (EC) No 1924/2006. 
CONCLUSIONS 
On the basis of the data presented, the Panel concludes that:  
 The food constituent, choline, which is the subject of the health claim, is sufficiently 
characterised. 
 The claimed effect proposed by the applicant is “development of brain”. The target 
population proposed by the applicant is infants and young children from birth to three years 
of age. The claimed effect is general and non-specific, and does not refer to any specific 
health claim as required by Regulation (EC) No 1924/2006. 
DOCUMENTATION PROVIDED TO EFSA 
Health claim application on choline and “development of brain” pursuant to Article 14 of Regulation 
(EC) No 1924/2006 (Claim serial No: 0054_FR). February 2008. Submitted by Specialised Nutrition 
Europe (formerly IDACE). 
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